Routine share plan transactions have no material impact on GSK's stock. Monitor upcoming quarterly results for fundamental drivers.
GSK drugs
GSK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $50.64entry
- T+1 · 4d ago −0.38%α −0.01% · $50.45
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK filed a Form 6-K reporting routine share acquisitions by multiple PDMRs (directors and senior executives) under the company's Share Reward Plan on November 10, 2026. The transactions are small in value and represent standard equity plan participation, not open-market purchases. No financial results or material corporate events are disclosed.
Key Facts
- Eight PDMRs and one PCA acquired ordinary shares under GSK's Share Reward Plan on November 10, 2026
- Each PDMR (except Victoria Whyte) acquired 12 ordinary shares at GBP 19.3453 per share; Victoria Whyte acquired 14 shares
- Maya Martinez-Davis acquired 9.264 notional ADS at $51.5400 in her Executive Supplemental Savings Plan account on November 9, 2026
- Total value of all ordinary share acquisitions is approximately GBP 2,088 (about $2,600)
- All transactions were pre-scheduled plan acquisitions, not discretionary open-market purchases
Financial Impact
Approximately GBP 2,088 total value of ordinary share acquisitions; negligible relative to GSK's $103.6B market cap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-009712 |
| Document: 0001654954-26-009712-index-headers.html | 0001654954-26-009712 |
| Document: 0001654954-26-009712-index.html | 0001654954-26-009712 |
| Document: 0001654954-26-009712.txt | 0001654954-26-009712 |
| Earnings Context (Synthetic; results releases only) | 0001654954-26-009712 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Viewing Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers